CELC Celcuity
- 17.840
- +0.170+0.96%
- 18.150
- +0.310+1.74%
Celcuity News
Top Five Cancer Types Dominate New US Cases as Biotech Sector Eyes $314B Market by 2032
According to a "highly troubling" new study, the rising number of cancer cases in young people is being attributed to "accelerated aging." Further...
Celcuity(CELC.US) Director Sells US$5,971 in Common Stock
$Celcuity(CELC.US)$ Director Buller Richard E sold 350 shares of common stock on Apr 24, 2024 at an average price of $17.06 for a total value of $5,971.Source: Announcement What is statement of change
Institutional Investors May Overlook Celcuity Inc.'s (NASDAQ:CELC) Recent US$51m Market Cap Drop as Long-term Gains Remain Positive
Key Insights Given the large stake in the stock by institutions, Celcuity's stock price might be vulnerable to their trading decisions 51% of the business is held by the top 6 shareholders 14% of
Needham: Reiterates Celcuity (CELC.US) rating and adjusted from buy to buy rating, target price is $24.00.
Needham: Reiterates Celcuity (CELC.US) rating and adjusted from buy to buy rating, target price is $24.00.
Needham Reiterates Buy on Celcuity, Maintains $24 Price Target
Needham analyst Gil Blum reiterates Celcuity with a Buy and maintains $24 price target.
Celcuity: A Promising Buy in Healthcare Innovation and Personalized Oncology Solutions
Celcuity To Present at Upcoming Needham and Stifel Investor Conferences
MINNEAPOLIS, April 04, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that Brian Sullivan, Chief
Celcuity (NASDAQ:CELC): A Biotech With Game-Changing Blockbuster Potential
Celcuity Inc. (NASDAQ:CELC) Q4 2023 Earnings Call Transcript
Celcuity Inc.'s Balancing Act: Navigating Financial Risks in Capital Raising Endeavors
Celcuity Is Maintained at Buy by Craig-Hallum
Celcuity Is Maintained at Buy by Craig-Hallum
Celcuity Up Over 20%, on Track for Highest Close Since September 2021 -- Data Talk
Celcuity Inc. (CELC) is currently at $21.88, up $3.72 or 20.48% --Would be highest close since Sept. 8, 2021, when it closed at $21.91 --On pace for largest percent increase since Dec. 19, 2022, whe
Craig-Hallum Maintains Buy on Celcuity, Raises Price Target to $25
Craig-Hallum analyst Alexander Nowak maintains Celcuity (NASDAQ:CELC) with a Buy and raises the price target from $20 to $25.
Craig Hallum Adjusts Celcuity Price Target to $25 From $20, Maintains Buy Rating
Celcuity (CELC) has an average rating of Buy and price targets ranging from $24 to $40, according to analysts polled by Capital IQ. Price: 20.83, Change: +2.67, Percent Change: +14.61
Stifel Nicolaus Reaffirms Their Buy Rating on Celcuity (CELC)
HC Wainwright & Co. Reiterates Buy on Celcuity, Maintains $27 Price Target
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Celcuity (NASDAQ:CELC) with a Buy and maintains $27 price target.
Celcuity Is Maintained at Buy by Needham
Celcuity Is Maintained at Buy by Needham
Analysts Are Bullish on These Healthcare Stocks: Celcuity (CELC), Cara Therapeutics (CARA)
Needham Maintains Buy on Celcuity, Raises Price Target to $24
Needham analyst Gil Blum maintains Celcuity (NASDAQ:CELC) with a Buy and raises the price target from $23 to $24.
Celcuity Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/28/2024 36.36% Needham $23 → $24 Maintains Buy 02/22/2024 127.27% Stifel → $40 Initiates Coverage On →
Analysis
Price Target
No Data
